



## **REVA Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum**

**San Diego, California** (Wednesday, November 14, 2018 - PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to announce that its Chief Executive Officer, Reggie Groves, is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York City.

The presentation delivered at the conference is available in the Investor Relations section of REVA’s website at [www.revamedical.com](http://www.revamedical.com) and will be presented from time to time by the Company at various other investor and analyst meetings.

### **About REVA Medical**

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is currently selling Fantom in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey. REVA is based in San Diego, California, and employs 45 people in the U.S. and Europe.

Fantom, Fantom Encore, MOTIV and Tyrocore are trademarks of REVA Medical, Inc.

#### **United States**

##### **Investor & Media Enquiries:**

REVA Medical, Inc.  
Brandi Roberts  
Chief Financial Officer  
+1 858-966-3003

David Schull  
Russo Partners  
+1 858-717-2310  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

#### **Australia**

##### **Investor Enquiries:**

Perpetuity Capital Pty Ltd  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

#### **Australia**

##### **Media Enquiries:**

Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722